| A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis JM Heckmann, H Uwimpuhwe, R Ballo, M Kaur, VB Bajic, S Prince Genes & Immunity 11 (1), 1-10, 2010 | 49 | 2010 |
| ARF6-regulated endocytosis of growth factor receptors links cadherin-based adhesion to canonical Wnt signaling in epithelia O Pellon-Cardenas, J Clancy, H Uwimpuhwe, C D'Souza-Schorey Molecular and cellular biology 33 (15), 2963-2975, 2013 | 43 | 2013 |
| NSAIDs induce apoptosis in nonproliferating ovarian cancer cells and inhibit tumor growth in vivo K Duncan, H Uwimpuhwe, A Czibere, D Sarkar, TA Libermann, PB Fisher, ... IUBMB life 64 (7), 636-643, 2012 | 38 | 2012 |
| FASN inhibition as a potential treatment for endocrine-resistant breast cancer A Gruslova, B McClellan, HU Balinda, S Viswanadhapalli, V Alers, ... Breast Cancer Research and Treatment 187 (2), 375-386, 2021 | 32 | 2021 |
| ELF4 is a critical component of a miRNA-transcription factor network and is a bridge regulator of glioblastoma receptor signaling and lipid dynamics A Kosti, J Chiou, GDA Guardia, X Lei, H Balinda, T Landry, X Lu, M Qiao, ... Neuro-oncology 25 (3), 459-470, 2023 | 11 | 2023 |
| Preclinical development of brain permeable ERβ agonist for the treatment of glioblastoma UP Pratap, M Tidwell, HU Balinda, NA Clanton, X Yang, ... Molecular cancer therapeutics 22 (11), 1248-1260, 2023 | 3 | 2023 |
| Mechanisms underlying melanoma invasion as a consequence of MLK3 loss HU Balinda, A Sedgwick, C D'Souza-Schorey Experimental cell research 415 (1), 113106, 2022 | 3 | 2022 |
| Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial HU Balinda, WJ Kelly, VG Kaklamani, KI Lathrop, MM Canola, ... Nature communications 15 (1), 6707, 2024 | 1 | 2024 |
| CTNI-36. Sacituzumab govitecan for recurrent glioblastoma W Kelly, H Balinda, P Ghamasaee, A Gilbert, J Michalek, P Surapaneni, ... Neuro-oncology 25 (Suppl 5), v82, 2023 | 1 | 2023 |
| CTNI-10. Sacituzumab govitecan for breast cancer brain metastasis H Balinda, W Kelly, P Ghamasaee, A Gilbert, J Michalek, V Kaklamani, ... Neuro-oncology 25 (Suppl 5), v75, 2023 | 1 | 2023 |
| Inhibition of FASN as a potential treatment of advanced endocrine therapy-resistant breast cancer. A Gunuganti, H Balinda, AJ Brenner Journal of Clinical Oncology 41 (16_suppl), e13077-e13077, 2023 | 1 | 2023 |
| Development of potent estrogen receptor beta agonists for treating glioblastoma UP Pratap, M Tidwell, HU Balinda, S Viswanadhapalli, GR Sareddy, ... Cancer Research 83 (7_Supplement), 1718-1718, 2023 | 1 | 2023 |
| LMD-14. Preclinical safety and activity of intraventricular Rhenium-186 Nanoliposome (186RNL) for leptomeningeal metastases M Guerra-Garcia, H Balinda, A Bao, M Garcia, A Gilbert, W Phillips, ... Neuro-oncology Advances 3 (Suppl 3), iii10, 2021 | 1 | 2021 |
| A phase II, multicenter, prospective study of sacituzumab govitecan in recurrent glioblastoma. W Kelly, C Cordova, BD Vaillant, H Balinda, J Michalek, A Gilbert, J Floyd, ... Journal of Clinical Oncology 42 (16_suppl), TPS2094-TPS2094, 2024 | | 2024 |
| Metabolic adaptations of glioblastoma in hypoxia is mediated by acox-1 A Bhattacharya, L Caflisch, H Balinda, A Lodi, M Zhou, M Li, J Chiou, ... Cancer Research 84 (6_Supplement), 4422-4422, 2024 | | 2024 |
| Abstract P1-14-04: A Phase 0 Clinical trial of Sacituzumab Govitecan in Patients with Breast Cancer Brain Metastases and Recurrent Glioblastoma P Ghamasaee, H Balinda, A Brenner, J Floyd Cancer Research 83 (5_Supplement), P1-14-04-P1-14-04, 2023 | | 2023 |
| Abstract P3-11-07: Inhibition of FASN as a potential treatment of advanced endocrine therapy-resistant breast cancer H Balinda Cancer Research 83 (5_Supplement), P3-11-07-P3-11-07, 2023 | | 2023 |
| HYPOXIA-INDUCED METABOLIC ADAPTATIONS THROUGH ACOX-1 IN GLIOBLASTOMA A Bhattacharya, L Caflisch, H Balinda, A Boyer, A Lodi, M Zhou, M Li, ... NEURO-ONCOLOGY 24, 25-26, 2022 | | 2022 |
| Abstract P5-05-10: Inhibition of FASN as a potential treatment of advanced therapy-resistant breast cancer HU Balinda Cancer Research 82 (4_Supplement), P5-05-10-P5-05-10, 2022 | | 2022 |
| Elucidation of MLK3 Signaling in Tumor Cell Invasion HU Balinda University of Notre Dame, 2020 | | 2020 |
